Kazia Therapeutics Expands Paxalisib Trial Into HR+/HER2- Breast Cancer

MT newswire2026/09/01 11:57

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

07:57 AM EDT, 09/01/2026 (MT Newswires) -- Kazia Therapeutics (KZIA) said Tuesday that it will expand its ongoing paxalisib clinical trial into hormone receptor-positive, HER2-negative advanced breast cancer after preclinical data showed anti-tumor activity and potential to resensitize tumors resistant to CDK4/6 inhibitors. The company said it is adding a three-arm expansion evaluating paxalisib with fulvestrant and palbociclib against fulvestrant alone. Kazia said it has also filed a provisional patent application covering the approach. The company expects to enroll the first patient before the end of 2026, complete enrollment by the end of 2027 and report full results in 2028, it said. Shares of Kazia Therapeutics were 2.8% higher in premarket trading.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

The U.S. Energy Information Administration (EIA) has raised its forecast for average Brent crude oil prices in 2026 and 2027 to $97 and $86, respectively, reflecting pressures from global inventory declines, Middle East supply disruptions, and rising transportation costs. As oil production in the Middle East gradually recovers and global inventories rebound from low levels, the EIA expects the average spot price of Brent crude to fall to $87 per barrel in the second quarter of 2027, and further decline to $77 per barrel by the fourth quarter.

华尔街见闻•2026/11/10 18:41